Morgan Stanley raised the firm’s price target on Johnson & Johnson to $197 from $190 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $230 from $209 at RBC Capital
- Johnson & Johnson price target raised to $232 from $215 at Citi
- Johnson & Johnson price target raised to $240 from $215 at HSBC
- Cautious Hold Rating for Johnson & Johnson Amid Promising Clinical Results and Competitive Challenges
- Carvykti strength holds, Legend Biotech weakness overdone, says RBC Capital